Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus BREO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus BREO ELLIPTA.
ARISTOGEL vs BREO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Category C
Category C
Corticosteroid
Corticosteroid/Beta-2 Agonist Combination